The drug udenafil is marketed under the trade name Zydena. It is within the PDE₅ inhibitor class. Like other PDE₅ inhibitors, it is used to treat erectile dysfunction. Udenafil was developed by Dong-A Pharmaceutical. It has fairly rapid onset of action, a Tmax typically within 0.5 to 1.5 hours and an elimination half-life in the range of about 10 to 13 hours, allowing therapeutic effect to persist into the 8 to 12 hour window in many subjects. Chemically, udenafil is a small molecule inhibitor selective for phosphodiesterase type 5 with higher affinity for PDE₅ than for PDE₆ and PDE₃ in vitro; it increases cGMP in corpus cavernosum smooth muscle leading to vasodilation in response to sexual stimulation. Udenafil is administered orally and undergoes hepatic metabolism predominantly via CYP3A4 with minor contribution from other CYP isoforms; common pharmacokinetic characteristics include moderate oral bioavailability, dose-proportional exposure over the therapeutic range, and renal excretion of metabolites. Standard clinical and pharmacodynamic assessments report improved erectile function scores versus baseline in controlled trials, and concomitant use with nitrates is contraindicated due to risk of clinically significant hypotension.
Typical analytical control for udenafil drug substance targets a low-impurity profile consistent with ICH principles; unspecified individual impurities are generally limited to 0.10 percent or lower and total impurities to 0.50 percent or lower, with qualification of impurities at higher levels using established toxicological thresholds. Known related compounds and process-related impurities include desmethyl and dealkylated metabolites, N-oxide variants, positional isomers originating from alkylation steps, residual synthetic intermediates such as substituted anilines and heterocyclic precursors, and potential oxidative degradation products; levels of residual solvents and heavy metals are controlled in accordance with ICH Q3C and relevant pharmacopeial limits. Identification and quantification are performed by orthogonal methods including HPLC with UV detection, LC-MS for mass confirmation, and NMR for structural elucidation where required. Stability studies guide specification tightening for degradants formed under forced degradation conditions such as hydrolysis and oxidation.
Udenafil is used to treat erectile dysfunction by inhibiting PDE₅, which enhances the nitric oxide–cGMP pathway in penile tissue to facilitate erection in response to sexual stimulation.
Udenafil is not approved by the United States Food and Drug Administration; it is approved and marketed in South Korea and some other countries under the trade name Zydena, but it is not an FDA-authorized product in the United States.
Clinical pharmacokinetic and pharmacodynamic data indicate onset of effect typically within 30 to 90 minutes and a duration of clinically relevant effect commonly reported in the 8 to 12 hour range, with measurable plasma concentrations and pharmacologic activity extending up to roughly 10 to 13 hours in many subjects.
